Skip to main content
Top

07-04-2017 | Psoriatic arthritis | Review | Article

Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain

Journal: Rheumatology International

Authors: Juan Carlos Torre-Alonso, Loreto Carmona, Mireia Moreno, Eva Galíndez, Jesús Babío, Pedro Zarco, Luis Linares, Eduardo Collantes-Estevez, Manuel Fernández Barrial, Juan Carlos Hermosa, Pablo Coto, Carmen Suárez, Raquel Almodóvar, Jesús Luelmo, Santos Castañeda, Jordi Gratacós

Publisher: Springer Berlin Heidelberg

Abstract

The objective is to establish recommendations, based on evidence and expert opinion, for the identification and management of comorbidities in patients with psoriatic arthritis (PsA). The following techniques were applied: discussion group, systematic review, and Delphi survey for agreement. A panel of professionals from four specialties defined the users, the sections of the document, possible recommendations, and what systematic reviews should be performed. A second discussion was held with the results of the systematic reviews. Recommendations were formulated in the second meeting and voted online from 1 (total disagreement) to 10 (total agreement). Agreement was considered if at least 70% voted ≥7. The level of evidence and grade of recommendation were assigned using the Oxford Centre for Evidence-Based Medicine guidance. The full document was critically appraised by the experts, and the project was supervised at all times by a methodologist. In a final step, the document was reviewed and commented by a patient and a health management specialist. Fourteen recommendations were produced, together with a checklist to facilitate the implementation. The items with the largest support from evidence were those related to cardiovascular disease and risk factors. The panel recommends paying special attention to obesity, smoking, and alcohol consumption, as they are all modifiable factors with an impact on treatment response or complications of PsA. Psychological and organizational aspects were also deemed important. We herein suggest practical recommendations for the management of comorbidities in PsA based on evidence and expert opinion.
Literature
1.
Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33(2):210–212PubMed
2.
Jamnitski A, Symmons D, Peters MJ, Sattar N et al (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211–216CrossRefPubMed
3.
Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J et al (2011) Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 30(7):877–885CrossRefPubMed
4.
Oliviero F, Scanu A, Galozzi P, Gava A et al (2013) Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Jt Bone Spine 80(3):287–290CrossRef
5.
Dauden E, Castaneda S, Suarez C, Garcia-Campayo J et al (2013) Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 27(11):1387–1404CrossRefPubMed
6.
Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35(12):680–689PubMedPubMedCentral
7.
Howick J, Chalmers I, Glasziou P, Greenhalgh T et al (2011) Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. http://​www.​cebm.​net/​index.​aspx?​o=​5653. Accessed 02 Nov 2015
8.
Rubiera Lopez G, Riera Velasco JR (2004) Program to improve care in chronic illnesses: application of the model of care in chronic illness. Aten Primaria 34(4):206–209CrossRefPubMed
9.
Peters MJ, Symmons DP, McCarey D, Dijkmans BA et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed
10.
Gomez Reino J, Loza E, Andreu JL, Balsa A et al (2011) Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin 7(5):284–298CrossRefPubMed
11.
Bori Segura G, Hernandez Cruz B, Gobbo M, Lanas Arbeloa A et al (2009) Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology. Reumatol Clin 5(1):3–12CrossRefPubMed
12.
Langman G, Hall PM, Todd G (2001) Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16(12):1395–1401CrossRefPubMed
13.
Shang Q, Tam LS, Yip GW, Sanderson JE et al (2011) High prevalence of subclinical left ventricular dysfunction in patients with psoriatic arthritis. J Rheumatol 38(7):1363–1370CrossRefPubMed
14.
Shang Q, Tam LS, Sanderson JE, Sun JP et al (2012) Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 51(12):2215–2223CrossRef
15.
Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A et al (2013) The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 72(5):715–720CrossRefPubMed
16.
Lin YC, Dalal D, Churton S, Brennan DM et al (2014) Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 66(1):97–103CrossRef
17.
Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P et al (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124(8):775 e771–776CrossRef
18.
Agca R, Heslinga SC, Rollefstad S, Heslinga M et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76(1):17–28CrossRefPubMed
19.
Maiques Galan A, Brotons Cuixart C, Villar Alvarez F, Martin Rioboo E et al (2014) Recomendaciones preventivas cardiovasculares. Aten Primaria 46(Suppl 4):3–15CrossRefPubMed
20.
Roubille C, Richer V, Starnino T, McCourt C et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489CrossRefPubMedPubMedCentral
21.
Kristensen SL, McInnes IB, Sattar N (2015) Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Ann Rheum Dis 74(2):321–322CrossRefPubMed
22.
Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G et al (2014) Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(4):600–607CrossRef
23.
Love TJ, Qureshi AA, Karlson EW, Gelfand JM et al (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147(4):419–424CrossRefPubMed
24.
Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41(7):1357–1365CrossRefPubMed
25.
Wang Y, Chen J, Zhao Y, Geng L et al (2008) Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 158:1134–1135CrossRefPubMed
26.
Li W, Han J, Qureshi AA (2012) Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71(8):1267–1272CrossRefPubMedPubMedCentral
27.
Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y (2014) Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 13(9):981–1000CrossRefPubMed
28.
Setty A, Curhan G, Choi H (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women. Nurses’ Health Study II. Arch Intern Med 167:1670–1675CrossRefPubMed
29.
Love TJ, Zhu Y, Zhang Y, Wall-Burns L et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273–1277CrossRefPubMedPubMedCentral
30.
Galindez E, Carmona L (2016) Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clin 12(6):307–312
31.
Almodovar R, Zarco P, Oton T, Carmona L (2017) Effect of weight loss on activity in psoriatic arthritis: a systematic review. Reumatol Clin. doi:10.​1016/​j.​reuma.​2017.​01.​010
32.
Debbanech M, Millsop J, Bhatia B, Koo J et al (2014) Diet and psoriasis, part I: Impact of weigt loss interventions. J Am Acad Dermatol 71:133–140CrossRef
33.
Martinez-Gonzalez MA, Garcia-Arellano A, Toledo E, Salas-Salvado J et al (2012) A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the PREDIMED trial. PLoS One 7(8):e43134CrossRefPubMedPubMedCentral
34.
Frankel H, Han J, Li T, Qureshi A (2012) The association between physical activity and the risk of incident psoriasis. Arch Dermatol 148(8):918–924CrossRefPubMedPubMedCentral
35.
Lubrano E, Spadaro A, Parsons W, Atteno M et al. (2009) Rehabilitation in psoriatic arthritis. J Rheumatol 2009(Suppl (83)):81–82
36.
Hagel S, Lindqvist E, Bremander A, Petersson I (2010) Team-based rehabilitation improves long-term aerobic capacity and health-related quality of life in patients with chronic inflammatory arthritis. Disabil Rehabil 32:1686–1696CrossRefPubMed
37.
Naldi L, Conti A, Cazzaniga S, Patrizi A et al (2014) Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 170:634–642CrossRefPubMed
38.
Li W, Han J, Qureshi AA (2012) Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71(6):804–808CrossRefPubMed
39.
Bremander A, Jacobsson LT, Bergman S, Haglund E et al (2015) Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort. Clin Rheumatol 34(3):579–583CrossRefPubMed
40.
Tillett W, Jadon D, Shaddick G, Cavill C et al (2013) Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 72(8):1358–1361CrossRefPubMed
41.
Hojgaard P, Glintborg B, Hetland ML, Hansen TH et al (2015) Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74(12):2130–2136CrossRefPubMed
42.
Carmona L, Abasolo L, Descalzo MA, Perez-Zafrilla B et al (2011) Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 41(1):71–80CrossRefPubMed
43.
Wu S, Cho E, Li WQ, Han J et al (2015) Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol 42(5):835–840CrossRefPubMedPubMedCentral
44.
Ewing JA (1984) Detecting alcoholism. The CAGE questionnaire. JAMA 252(14):1905–1907CrossRefPubMed
45.
Babor TB, Higgins-Biddle JC, Saunders JB, Monteiro MG (2001) AUDIT: the alcohol use disorders identification test: guidelines for use in primary care, 2nd edn. World Health Organization, Department of Mental Health and Substance Dependence
46.
Freire M, Rodriguez J, Moller I, Valcarcel A et al (2011) Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7(1):20–26CrossRefPubMed
47.
DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160(14):2101–2107CrossRefPubMed
48.
Sumlin LL, Garcia TJ, Brown SA, Winter MA et al (2014) Depression and adherence to lifestyle changes in type 2 diabetes: a systematic review. Diabetes Educ 40(6):731–744CrossRefPubMed
49.
Magrey MN, Antonelli M, James N, Khan MA (2013) High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis 2013:762921CrossRefPubMedPubMedCentral
50.
Husted JA, Thavaneswaran A, Chandran V, Gladman DD (2013) Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 40(8):1349–1356CrossRefPubMed
51.
Ortega Orcos R, Salinero Fort MA, Kazemzadeh Khajoui A, Vidal Aparicio S et al (2007) Validation of 5 and 15 items Spanish version of the geriatric depression scale in elderly subjects in primary health care setting. Rev Clin Esp 207(11):559–562CrossRefPubMed
52.
Goldberg DP, Hillier VF (1979) A scaled version of the General Health Questionnaire. Psychol Med 9(1):139–145CrossRefPubMed
53.
Molina-Leyva A, Jimenez-Moleon JJ, Naranjo-Sintes R, Ruiz-Carrascosa JC (2015) Sexual dysfunction in psoriasis: a systematic review. J Eur Acad Dermatol Venereol 29(4):649–655CrossRefPubMed
54.
Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW et al (2011) Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 164(6):1247–1255CrossRefPubMed
55.
Billups KL (2005) Erectile dysfunction as a marker for vascular disease. Curr Urol Rep 6(6):439–444CrossRefPubMed
56.
Gonzalez-Juanatey JR, Alegria Ezquerra E, Gomis Barbera R, Salvador Taboada MJ et al (2009) Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study. Med Clin (Barc) 132(8):291–297CrossRef
57.
Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT (2000) Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 59(1):67–70CrossRefPubMedPubMedCentral
58.
Queiro R, Torre JC, Belzunegui J, Gonzalez C et al (2002) Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 31(4):264–270CrossRefPubMed
59.
Niccoli L, Nannini C, Cassarà E, Kaloudi O et al (2012) Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis 15(4):414–418CrossRefPubMed
60.
Durrani K, Foster CS (2005) Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol 139(1):106–111CrossRefPubMed
61.
Rohekar S, Tom BD, Hassa A, Schentag CT et al (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58(1):82–87CrossRefPubMed
62.
Gross RL, Schwartzman-Morris JS, Krathen M, Reed G et al (2014) A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 66(6):1472–1481CrossRefPubMedPubMedCentral
63.
Margolis D, Bilker W, Hennessy S, Vittorio C et al (2001) The risk of malignancy associated with psoriasis. Arch Dermatol 137(6):778–783PubMed
64.
Husni ME, Mease PJ (2010) Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 12(4):281–287CrossRefPubMed
65.
Naldi L (2010) Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol 28(1):88–92CrossRefPubMed
66.
Stern RS, Lunder EJ (1998) Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 134(12):1582–1585CrossRefPubMed
67.
Patel RV, Clark LN, Lebwohl M, Weinberg JM (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60(6):1001–1017CrossRefPubMed
68.
Roubille C, Richer V, Starnino T, McCourt C et al (2015) Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol 42(10):1767–1780CrossRefPubMed
69.
Treadwell JR, Lucas S, Tsou AY (2014) Surgical checklists: a systematic review of impacts and implementation. BMJ Qual Saf 23(4):299–318CrossRefPubMed
70.
Grossman JM, Gordon R, Ranganath VK, Deal C et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515–1526CrossRef
71.
Gisondi P, Targher G, Cagalli A, Girolomoni G (2014) Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol 70(1):127–130CrossRefPubMed
72.
Merola JF, Wu S, Han J, Choi HK et al (2015) Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 74(8):1495–1500CrossRefPubMed
73.
Lopez-Reyes A, Hernandez-Diaz C, Hofmann F, Pineda C (2012) Gout mimicking psoriatic arthritis flare. J Clin Rheumatol 18(4):220CrossRefPubMed
74.
Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I et al (2009) Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 39(3):157–162CrossRefPubMed
75.
Clarson L, Chandratre P, Hider S, Belcher J et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J. Prev Cardiol 22(3):335–343CrossRef
76.
McGonagle D, Hermann KG, Tan AL (2015) Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford) 54(1):29–38CrossRef
77.
Gulati AM, Semb AG, Rollefstad S, Romundstad PR et al (2016) On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. Ann Rheum Dis 75(5):819–824CrossRefPubMed
78.
Eder L, Chandran V, Gladman DD (2014) The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73(11):1990–1996CrossRefPubMed
79.
Berdal G, Smedslund G, Dagfinrud H, Hagen KB et al (2015) Design and effects of supportive followup interventions in clinical care of patients with rheumatic diseases: a systematic review with meta-analysis. Arthritis Care Res (Hoboken) 67(2):240–254CrossRef
80.
Betteridge N, Boehncke WH, Bundy C, Gossec L et al (2016) Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol 30(4):576–585CrossRefPubMedPubMedCentral